Large Ischemic Core, Mechanical Thrombectomy
Conditions
Keywords
Acute cerebral infarction due to large vessel occlusion, Mechanical thrombectomy, Ischemic stroke
Brief summary
RESCUE-Japan LIMIT(Recovery by Endovascular Salvage for Cerebral Ultra-acute Embolism Japan Large IscheMIc core Trial) is a prospective, open label, blinded endpoint (PROBE), Japanese, two-arm, randomized, controlled, post-market study to compare the effectiveness of endovascular treatment as compared to best medical treatment alone in the acute ischemic stroke patients with an low ASPECTS (CT-ASPECTS 3-5 or DWI-ASPECTS 3-5). The purpose of this study is to investigate the efficacy of endovascular treatment for acute large vessel occlusion with large ischemic core (CT-ASPECT score 3-5 or DWI-ASPECT score 3-5).
Detailed description
In the American Heart Association guideline 2018, endovascular therapy (EVT) has been strongly recommended as class of recommendation (COR) I for for the patients with acute cerebral large vessel occlusion (LVO), the Alberta Stroke Program Early CT Score (ASPECTS) 6 or more. The efficacy of EVT for the patients with low ASPECTS remains unclear. This study is a prospective, open label, blinded endpoint (PROBE), Japanese, two-arm, randomized, controlled, post-market study to compare the effectiveness of endovascular treatment as compared to best medical treatment alone for acute large vessel occlusion patients with large ischemic core (ASPECTS 3-5 or DWI-ASPECTS 3-5). Up to 200 subjects will be enrolled in the study and randomized for the Intention to treat analysis set. The randomization will be stratified by treatment institutes, patient's age (less than 75 years old or not), time from symptom onset (0-2 hours or more than 2 hours), and stroke severity (NIHSS 21 or more/less than 21), and administration of rt-PA. Subjects who meet the inclusion criteria will be randomized in a 1:1 ratio to one of the following two treatment arms: Arm 1: best medical treatment Arm 2: best medical treatment plus endovascular treatment Primary outcome of this study is to investigate efficacy of endivascular treatment in acute stroke patients with large ischemic core (ASPECTS 3-5 or DWI-ASPECTs 3-5) as compared to best medical treatment alone. Approximately 40 sites in Japan Patients presenting with acute ischemic stroke (AIS) based on focal occlusion in the M1 segment of the middle cerebral artery (MCA), and/or the intracranial segment of the distal internal carotid artery (ICA), determined by Magnetic Resonance Angiography (MRA) or Computed Tomographic Angiography (CTA), and who meet all eligibility criteria will be considered for study enrollment.
Interventions
PROCEDUREEndovascular treatment
Acute thrombectomy
Sponsors
Hyogo Medical University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Acute cerebral infarction 2. Age ≥ 18 3. NIHSS ≥ 6 4. Prestroke Modified Rankin Score 0-1 5. ICA or M1 Occlusion on CT angiography or MR angiography 6. ASPECTS 3-5 or DWI-ASPECTS 3-5 7. Randamization can be finished within 6 hours from last known well time, or 6 to 24 hours from last well known well time without positive lesion on MRI-FLAIR image. 8. Endovascular treatment can be initiatedwithin 60 minutes from randomization 9. Patient or Legally Authorized Representative has signed the Informed Consent form
Exclusion criteria
1. Significant mass effect with midline shift 2. Known allergy to contrast agents 3. Evidence of acute intracranial hemorrhage 4. Female who is pregnant or suspicision of pregnant 5. Clinical evidence of chronic occlusion 6. High risk of hemorrhage (platelet \< 40,000 /µL, APTT \> 50 second or PT-INR \> 3.0) 7. Participating in any other therapeutic investigational trial 8. Subjects who, in the judgment of the investigator, are likely to be non-compliant or uncooperative during the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| modified Rankin Scale ≤3 at 90 days | 90 days | The primary endpoint of the trial is the modified Rankin Scale (mRS) ≤3 at 90 days post-stroke.The scale runs from 0-6 with 0 being perfect health without symptoms to 6 being death. 0: No symptoms. 1. No significant disability. Able to carry out all usual activities, despite some symptoms. 2. Slight disability. Able to look after own a符airs without assistance, but unable to carry out all previous activities. 3. Moderate disability. Requires some help, but able to walk unassisted. 4. Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. 5. Severe disability. Requires constant nursing care and a悦ention, bedridden, incontinent. 6. Dead. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| modified Rankin Scale≤1 at 90 days | 90 days | Excellent outcome as difined by modified Rankin Scale≤1 at 90 days |
| Distribution of patients across the ordinal modified Rankin scale | 90 days | The difference in linear trends in ordinal mRS outcomes between treatment groups (mRS shift analysis) |
| NIHSS improvement 8 points or more at 48 hours | 48 hours | Early improvement of neulogical findings |
| Symptomatic intracranial hemorrhage within 48 hours | 48 hours | Defined as NIHSS worsening of 4 or more points associated with ICH within 48 hours of randomization |
| modified Rankin Scale≤2 at 90 days | 90 days | Functional independence as difined by modified Rankin ScalemRS≤2 at 90 days |
| Death | 90 days | Death due to any cause at 90 days |
| Recurrence of cerebral infarction within 90 days | 90 days | Recurrence of cerebral infarction |
| Propotion of subjects who required decompressive craniectomy within 7 days | 7 days | Propotion of subjects who had space-occupying infarction (malignant brain edema) and requred decompressive craniectomy within 7 days |
| Intracranial hemorrhage within 48 hours | 48 hours | The incidence of hemorrhage |
Countries
Japan
Outcome results
None listed